A Primer and Practical Approach to Cancer Checkpoint Inhibitors for the Dermatologist

The session on cancer checkpoint inhibitors, moderated by Oliver Wisco, aims to equip dermatologists with knowledge about these crucial immuno-oncology therapies increasingly used in cancer treatment. It features notable speakers specializing in dermatology and immunology, including Jason Hawks, Dr. Michael Tetsoff, Noah Hornick, and Dr. Jen Choi. Wisco emphasizes the importance of addressing both the therapeutic potential and the adverse effects associated with checkpoint inhibitors as they relate to skin conditions such as squamous cell carcinoma and melanoma. He recounts patient experiences illustrating systemic barriers to care and the challenges dermatologists face when managing treatment options amidst these hurdles. Key points include a discussion on FDA-approved agents and National Comprehensive Cancer Network (NCCN) guidelines alongside recommendations for managing adverse reactions. The dialogue shifts to practical cases, highlighting patient stories and how multidisciplinary care coordination can improve patient outcomes. For instance, the group discusses various therapeutic regimes for patients with skin cancers and addresses the psychological and logistical difficulties faced by patients needing such interventions. Ultimately, the session seeks to foster an understanding of when to utilize immunotherapy, incorporating the latest evidence to help guide clinical decisions in dermatology.